Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNYSE:MRK Merck & Co., Inc. (MRK) Stock Price, News & Analysis $141.03 -0.79 (-0.55%) Closing price 03:59 PM EasternExtended Trading$143.01 +1.98 (+1.40%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Merck & Co., Inc. Stock (NYSE:MRK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Merck & Co., Inc. alerts:Sign Up Key Stats Today's Range$139.21▼$142.4050-Day Range$135.34▼$156.5452-Week Range$82.01▼$156.92Volume8.22 million shsAverage Volume10.66 million shsMarket Capitalization$347.95 billionP/E Ratio112.83Dividend Yield2.41%Price Target$153.12Consensus RatingModerate Buy Company Overview Merck & Co., Inc. is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide. Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes. Its portfolio also includes products such as Bridion, which reverses certain effects of muscle-relaxing medicines used during surgery. Through Merck Animal Health, the company provides vaccines, pharmaceutical products and technology-enabled solutions for livestock, companion animals and aquaculture. The company traces its roots to the U.S. operations established by the Merck family in 1891 and operates independently from Germany-based Merck KGaA, which uses the name EMD in the United States and Canada. Merck & Co. has research, manufacturing and commercial operations across North America, Europe, Asia-Pacific, Latin America, Africa and other international markets. Robert M. Davis serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Merck & Co., Inc. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreMRK MarketRank™: 4.563466285565 of 5 starsMerck & Co., Inc. scored higher than 91% of companies evaluated by MarketBeat, and ranked 24th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingMerck & Co., Inc. has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on no strong buy ratings, 17 buy ratings, 9 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Merck & Co., Inc. is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMerck & Co., Inc. has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merck & Co., Inc.'s stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth250.76% Earnings GrowthEarnings for Merck & Co., Inc. are expected to grow by 250.76% in the coming year, from $2.64 to $9.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merck & Co., Inc. is 112.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Merck & Co., Inc. is 112.83, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.86.Price to Earnings Growth RatioMerck & Co., Inc. has a PEG Ratio of 6.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMerck & Co., Inc. has a P/B Ratio of 6.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merck & Co., Inc.'s valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.09% of the float of Merck & Co., Inc. has been sold short.Short Interest Ratio / Days to CoverMerck & Co., Inc. has a short interest ratio ("days to cover") of 2.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Merck & Co., Inc. has recently decreased by 5.12%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldMerck & Co., Inc. pays a meaningful dividend of 2.34%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMerck & Co., Inc. has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Merck & Co., Inc. is 272.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 36.72% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.Read more about Merck & Co., Inc.'s dividend. News and Social Media3.4 / 5News Sentiment0.48 News SentimentMerck & Co., Inc. has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 83 news articles for Merck & Co., Inc. this week, compared to 9 articles on an average week.Search Interest51 people have searched for MRK on MarketBeat in the last 30 days. This is an increase of 16% compared to the previous 30 days.MarketBeat Follows39 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is an increase of 290% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,977,783.00 in company stock.Percentage Held by Insiders0.17% of the stock of Merck & Co., Inc. is held by insiders.Percentage Held by Institutions76.07% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merck & Co., Inc.'s insider trading history. Receive MRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRK Stock News HeadlinesMerck's KEYTRUDA Cuts Progression Risk By 43% In Phase 3 Endometrial Cancer Trial4 hours ago | rttnews.comDielectric Materials for Display - Global Strategic Business Report 2026: Capture the $28.7B Revenue Surge Through 2032 | Applied Materials, Corning, BASF, DuPont, and Merck Dominate4 hours ago | finance.yahoo.com80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.October 28 at 1:00 AM | The Tomorrow Investor (Ad)3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and GileadOctober 28 at 8:14 AM | 247wallst.comMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? (MRK)Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.October 27 at 10:20 AM | marketbeat.comMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? (MRK)Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.October 27 at 10:20 AM | marketbeat.comBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (MRK)MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.October 26 at 8:35 AM | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (MRK)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23, 2026 | marketbeat.comSee More Headlines MRK Stock Analysis - Frequently Asked Questions How have MRK shares performed this year? Merck & Co., Inc.'s stock was trading at $105.20 at the beginning of 2026. Since then, MRK shares have increased by 34.1% and is now trading at $141.0330. How were Merck & Co., Inc.'s earnings last quarter? Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Tuesday, August, 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm's revenue was up 5.1% on a year-over-year basis. Read the conference call transcript. Is Merck & Co., Inc. buying back stock? Merck & Co., Inc.'s board approved a stock buyback plan on Tuesday, January 28th 2025, which allows the company to buy back $10 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its stock is undervalued. Who are Merck & Co., Inc.'s major shareholders? Merck & Co., Inc.'s top institutional investors include Robeco Institutional Asset Management B.V. (0.09%), Assenagon Asset Management S.A. (0.06%), Asset Management One Co. Ltd. (0.06%) and Mn Services Vermogensbeheer B.V. (0.03%). Insiders that own company stock include Robert M Davis, Richard R Deluca, Dean Y Li, Caroline Litchfield, Jennifer Zachary, Chirfi Guindo, David Michael Williams, Steven Mizell, Johannes Jacobus Oosthuizen, Joseph Romanelli, David R Maraldo, Dalton E Smart III, Cristal N Downing and Inge G Thulin. View institutional ownership trends. How do I buy shares of Merck & Co., Inc.? Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merck & Co., Inc. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merck & Co., Inc. investors own include Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Verizon Communications (VZ), Chevron (cvx) and Intel (INTC). Company Calendar Last Earnings8/04/2026Record date for 10/7 Dividend9/15/2026Ex-Dividend for 10/7 Dividend9/15/2026Dividend Payable10/07/2026Today10/28/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MRK's financial health is in the Green zone, according to TradeSmith. MRK has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:MRK CIK310158 Webwww.merck.com Phone(908) 740-4000Fax908-735-1253Employees75,000Year Founded1891Price Target and Rating Average Price Target for Merck & Co., Inc.$153.12 High Price Target$180.00 Low Price Target$92.00 Potential Upside/Downside+8.6%Consensus RatingModerate Buy Rating Score (0-4)2.59 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)$1.25 Trailing P/E Ratio112.83 Forward P/E Ratio53.42 P/E Growth6.74Net Income$18.25 billion Net Margins4.77% Pretax Margin8.94% Return on Equity16.73% Return on Assets6.13% Debt Debt-to-Equity Ratio1.22 Current Ratio1.32 Quick Ratio1.10 Sales & Book Value Annual Sales$65.01 billion Price / Sales5.35 Cash Flow$11.09 per share Price / Cash Flow12.72 Book Value$21.22 per share Price / Book6.65Miscellaneous Outstanding Shares2,467,170,000Free Float2,462,978,000Market Cap$347.95 billion OptionableOptionable Beta0.21 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:MRK) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck & Co., Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck & Co., Inc. With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
